

Peter Bacchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6856519/publications.pdf>

Version: 2024-02-01

106
papers

7,847
citations

76196

40
h-index

51492

86
g-index

109
all docs

109
docs citations

109
times ranked

8558
citing authors

#	ARTICLE	IF	CITATIONS
1	Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 87-99.	1.4	0
2	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , 2021, 224, 1209-1218.	1.9	18
3	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1169, 122467.	1.2	3
4	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. <i>BMC Infectious Diseases</i> , 2021, 21, 99.	1.3	3
5	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	2.7	24
6	Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2020, 71, 1517-1523.	2.9	17
7	Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 315-318.	2.3	2
8	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. <i>Aids</i> , 2020, 34, 255-260.	1.0	38
9	Human Immunodeficiency Virus (HIV)-Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 744-755.	1.9	39
10	Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	10
11	Effect of a Patient-Centered Decision Support Tool on Rates of Trial of Labor After Previous Cesarean Delivery. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2151.	3.8	21
12	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	2
13	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. <i>Journal of Virology</i> , 2020, 94, .	1.5	20
14	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. <i>JCI Insight</i> , 2020, 5, .	2.3	140
15	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15029.	0.5	14
16	Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	2
17	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 692-702.	2.3	29
18	The Other Arbitrary Cutoff. <i>American Statistician</i> , 2019, 73, 413-414.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121729.	1.2	9
20	The association of patient preferences and attitudes with trial of labor after cesarean. <i>Journal of Perinatology</i> , 2019, 39, 1340-1348.	0.9	10
21	Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval—Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2019, 39, 899-911.	1.2	1
22	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 2214.	1.5	38
23	Women's Preferences Regarding the Processes and Outcomes of Trial of Labor After Cesarean and Elective Repeat Cesarean Delivery. <i>Journal of Women's Health</i> , 2019, 28, 1143-1152.	1.5	9
24	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. <i>ERJ Open Research</i> , 2019, 5, 00046-2019.	1.1	9
25	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. <i>PLoS Computational Biology</i> , 2019, 15, e1006849.	1.5	22
26	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019, 5, 167-173.	0.3	5
27	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 72-77.	0.9	50
28	Measuring Adherence to Antiretroviral Therapy via Hair Concentrations in India. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 202-206.	0.9	18
29	Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00010.	1.3	27
30	RAPID antiretroviral therapy. <i>Aids</i> , 2019, 33, 825-832.	1.0	83
31	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. <i>Aids</i> , 2019, 33, 1657-1662.	1.0	11
32	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	2.9	22
33	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	1.9	73
34	Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. <i>Journal of General Internal Medicine</i> , 2019, 34, 2005-2013.	1.3	35
35	Statistical analysis of single-copy assays when some observations are zero. <i>Journal of Virus Eradication</i> , 2019, 5, 167-173.	0.3	5
36	Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 202-208.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Ovarian aging is associated with gray matter volume and disability in women with MS. <i>Neurology</i> , 2018, 90, e254-e260.	1.5	41
38	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	2.9	82
39	A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 949-956.	2.3	1
40	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 431-441.	0.7	11
41	Impact of Moderate Alcohol Discontinuation on Insulin Action and Secretion in Latinos With and Without Hepatitis C. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 492-499.	1.4	1
42	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	1.0	14
43	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	3.2	42
44	A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 331-339.	2.0	32
45	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7795-E7804.	3.3	121
46	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	1.1	18
47	Life-Space Assessment Predicts Hospital Readmission in Home-Limited Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1004-1011.	1.3	25
48	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	0.5	52
49	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 911-919.	1.9	95
50	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 658-667.	0.5	22
51	Impact of a Mindfulness-Based Weight-Loss Intervention on Sleep Quality Among Adults with Obesity: Data from the SHINE Randomized Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 188-195.	2.1	14
52	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	1.0	47
53	Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 46.e1-46.e11.	0.7	21
54	An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1069-1070.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. <i>Clinical Infectious Diseases</i> , 2017, 65, 1695-1702.	2.9	4
56	Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. <i>Obesity</i> , 2016, 24, 794-804.	1.5	113
57	A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 991-992.	0.6	6
58	Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2417-2425.	1.1	2
59	Effects of a mindfulness-based intervention on mindful eating, sweets consumption, and fasting glucose levels in obese adults: data from the SHINE randomized controlled trial. <i>Journal of Behavioral Medicine</i> , 2016, 39, 201-213.	1.1	124
60	Best Practices for Biostatistical Consultation and Collaboration in Academic Health Centers. <i>American Statistician</i> , 2016, 70, 187-194.	0.9	22
61	Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0155887.	1.1	15
62	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016, 12, e1005761.	2.1	350
63	Effect of Present-on-Admission (POA) Reporting Accuracy on Hospital Performance Assessments Using Risk-Adjusted Mortality. <i>Health Services Research</i> , 2015, 50, 922-938.	1.0	10
64	Swiss medical centres vary significantly when it comes to outcomes of neonates with a very low gestational age. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, 872-879.	0.7	24
65	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. <i>Lancet HIV</i> , 2015, 2, e520-e529.	2.1	213
66	Outcomes after ileoanal pouch surgery in frail and older adults. <i>Journal of Surgical Research</i> , 2015, 198, 327-333.	0.8	37
67	Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. <i>Transfusion</i> , 2015, 55, 947-952.	0.8	40
68	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. <i>Journal of Infectious Diseases</i> , 2015, 212, 596-607.	1.9	138
69	Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1009-1014.	0.5	32
70	Tired telomeres: Poor global sleep quality, perceived stress, and telomere length in immune cell subsets in obese men and women. <i>Brain, Behavior, and Immunity</i> , 2015, 47, 155-162.	2.0	62
71	Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0129100.	1.1	43
72	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	1.1	125

#	ARTICLE	IF	CITATIONS
73	Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. <i>Neurology</i> , 2014, 83, 1705-1711.	1.5	51
74	Increases in Mindful Eating Predict Reductions in Consumption of Sweets and Desserts: Data from the Supporting Health by Integrating Nutrition and Exercise (SHINE) Clinical Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, A17-A17.	2.1	1
75	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. <i>Journal of Infectious Diseases</i> , 2013, 208, 1202-1211.	1.9	285
76	Increase in 2â€œLong Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1436-1442.	1.9	151
77	A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 206, 1453-1461.	1.9	59
78	Breaking Free of Sample Size Dogma to Perform Innovative Translational Research. <i>Science Translational Medicine</i> , 2011, 03, 87ps24.	5.8	122
79	Progression of Biopsy-Measured Liver Fibrosis in Untreated Patients with Hepatitis C Infection: Non-Markov Multistate Model Analysis. <i>PLoS ONE</i> , 2011, 6, e20104.	1.1	11
80	Current sample size conventions: Flaws, harms, and alternatives. <i>BMC Medicine</i> , 2010, 8, 17.	2.3	136
81	Simple, Defensible Sample Sizes Based on Cost Efficiency. <i>Biometrics</i> , 2008, 64, 577-585.	0.8	74
82	Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. <i>BMC Infectious Diseases</i> , 2007, 7, 145.	1.3	20
83	Uncertainty due to model choice in variant Creutzfeldtâ€œJakob disease projections. <i>Statistics in Medicine</i> , 2005, 24, 83-93.	0.8	3
84	Ethics and Sample Size. <i>American Journal of Epidemiology</i> , 2005, 161, 105-110.	1.6	102
85	Age and Variant Creutzfeldt-Jakob Disease. <i>Emerging Infectious Diseases</i> , 2003, 9, 1611-1612.	2.0	11
86	Generalized Additive Models with Interval-Censored Data and Time-Varying Covariates: Application to Human Immunodeficiency Virus Infection in Hemophiliacs. <i>Biometrics</i> , 2002, 58, 443-447.	0.8	11
87	Peer review of statistics in medical research: the other problem. <i>BMJ: British Medical Journal</i> , 2002, 324, 1271-1273.	2.4	119
88	Peripheral Vascular Disease Risk Factors among Patients Undergoing Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 497-503.	3.0	150
89	Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. <i>Hepatology</i> , 2001, 33, 1394-1403.	3.6	1,931
90	Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. <i>Clinical Transplantation</i> , 2000, 14, 167-173.	0.8	49

#	ARTICLE	IF	CITATIONS
91	Changes in Bone Resorption During the Menstrual Cycle. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 609-615.	3.1	58
92	Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. <i>Liver Transplantation</i> , 1999, 5, 136-143.	1.9	35
93	Comparison of Custom and Prefabricated Orthoses in the Initial Treatment of Proximal Plantar Fasciitis. <i>Foot and Ankle International</i> , 1999, 20, 214-221.	1.1	323
94	Biliary complications of reduced-organ liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 343-349.	1.9	60
95	INCIDENCE OF HIV-RELATED DEATHS IN THE UNITED STATES: SEASONALITY AND TREND. <i>Statistics in Medicine</i> , 1997, 16, 645-652.	0.8	1
96	Survival trees with time-dependent covariates: Application to estimating changes in the incubation period of AIDS. <i>Lifetime Data Analysis</i> , 1995, 1, 35-47.	0.4	30
97	Seasonal and other short-term influences on United States AIDS incidence. <i>Statistics in Medicine</i> , 1994, 13, 1921-1931.	0.8	18
98	Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. <i>Hepatology</i> , 1994, 20, 105-110.	3.6	139
99	Interferon- α therapy for hepatitis c virus infection after liver transplantation. <i>Hepatology</i> , 1994, 20, 773-779.	3.6	177
100	Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. <i>Hepatology</i> , 1994, 20, 1152-1155.	3.6	136
101	Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. <i>Hepatology</i> , 1994, 20, 1152-1155.	3.6	25
102	Estimating the Incubation Period of AIDS by Comparing Population Infection and Diagnosis Patterns. <i>Journal of the American Statistical Association</i> , 1990, 85, 1002-1008.	1.8	101
103	Additive Isotonic Models. <i>Journal of the American Statistical Association</i> , 1989, 84, 289-294.	1.8	56
104	Incubation period of AIDS in San Francisco. <i>Nature</i> , 1989, 338, 251-253.	13.7	360
105	RISK FACTORS FOR AIDS AND HIV SEROPOSITIVITY IN HOMOSEXUAL MEN. <i>American Journal of Epidemiology</i> , 1987, 125, 1035-1047.	1.6	187
106	Estimating the Incubation Period of AIDS by Comparing Population Infection and Diagnosis Patterns. , 0, .		23